AzTrials
AzTrials

CataractPHY2107NCT05255029

Clinical Investigation of a Monofocal Toric Intra Ocular Lens (IOL) in Cataractous Eyes

A study testing POD T 49P implantation experimental in people with Cataract and Lens Opacities, run by Beaver-Visitec International, Inc. at 4 sites in Japan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC (model POD T 49P). Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Cataract, Lens Opacities, Astigmatism
What is being tested?
POD T 49P implantation experimental
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
4 sitesJapan
Study dates
24 Dec 2021to 28 Feb 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

The patient who meets all criteria specified in the following 1) through 8)

  1. Adults, 20 years of age or older at the time of informed consent, of either gender, diagnosed with cataract;
  2. Able to comprehend and sign a statement of informed consent;
  3. Willing and able to complete all required postoperative visits;
  4. Calculated lens power within the available range;
  5. Subject with corneal astigmatism or subjects who is judged by the investigator or investigator to correct of astigmatism as a result of considering the predicted surgical induced astigmatism.
  6. Planned cataract removal by phacoemulsification;
  7. Target postoperative refraction is emmetropia and potential postoperative Collected Distance Visual Acuity (CDVA) of 0.5 decimal or better in both eyes;
  8. Clear intraocular media other than cataract in both eyes;

[Justification for the inclusion criteria]

1 and 6: Cataract extraction is the indication of the clinical study. 2 and 3: One of GCP requirements 4 and 5: Essential condition for implant of the investigational lens. 7 and 8: Conditions to minimize the potential non-IOL factors which may affect the visual acuity data

(3) Exclusion Criteria [Exclusion Criteria Prior to Surgery] The patient who meets any criteria specified in the following 1) through 20).

  1. Subjects with diseases that affect postoperative visual acuity in the cornea (keratitis, corneal degeneration, corneal dilatation, corneal edema);
  2. Previous corneal transplant;
  3. Previous refractive surgery;
  4. Irregular corneal aberration
  5. Subjects with diseases that affect postoperative visual acuity in the retina (retinal degeneration, diabetic retinopathy, retinal detachment);
  6. Poor mydriasis;
  7. Glaucoma or ocular hypertension;
  8. Optic nerve atrophy;
  9. Extremely shallow anterior chamber;
  10. Aniridia;
  11. Iris neovascularization;
  12. Microphthalmos;
  13. Amblyopia;
  14. Rubella, atopic or traumatic cataract;
  15. Recurrent severe anterior or posterior segment inflammation of unknown etiology;
  16. Subjects who may be expected to require ocular surgery during this study;
  17. The axial length cannot be measured with an optical biometry;
  18. Pregnancy, lactating or possible pregnant;
  19. Participation in any clinical study (drug or device) within 3 months prior to participating this study, planned participation another clinical study during this study, or currently participating in another study.
  20. Disqualified by the investigator or the sub-investigator because of physical or ophthalmic diseases

[Exclusion Criteria During Surgery] The patient who meets any criteria specified in the following 1) through 8).

  1. Mechanical or surgical manipulation required to enlarge the pupil;
  2. Excessive iris mobility;
  3. Uncontrollable intraocular pressure;
  4. Continuous Curvilinear Capsulorrhexis (CCC) with incomplete circle or tear;
  5. Zonular or capsular rupture or tear;
  6. Significant anterior chamber hyphema;
  7. Significant vitreous loss;
  8. IOL could not be fixed in the lens capsule;

In the event of zonular damage, capsulorhexis tear, or decentered capsulorhexis during surgery, the surgeon should decide whether the stability of the Intra Ocular Lens (IOL) would be compromised by the complication. If the IOL stability would be compromised, the investigational IOL should not be implanted, the subject should be discontinued from the study, and the surgeon should make arrangements to implant an alternative non-investigational IOL.

[Justifications for the exclusion criteria] {Exclusion Criteria Prior to Surgery} 1, 2, 3, 4, 5, 7, 8, 14, 15, 16 and 20: Factors potentially affecting effectiveness evaluability and criteria to secure safety of study subjects 6, 13 and17: Factors potentially affecting effectiveness evaluability 9, 10, 11, 12, 18 and 19: Criteria to secure safety of study subjects

{Exclusion Criteria During Surgery}

1, 2, 4, 5 and 8: Factors potentially affecting effectiveness evaluability 3, 6 and 7: Criteria to secure safety of study subjects

Trial locations and contacts

4 sites in 1 country.

Japan4 sites
  • Roppongi Shiba Eye Clinic

    Minato-Ku, Tokyo

  • Miyata Eye Hospital

    Miyazaki

  • Chukyo Eye Clinic

    Nagoya, Aichi-ken

  • Fujita Eye Clinic

    Tokushima

Other trials in Japan

About this study

Official title: Clinical Investigation of the Monofocal Toric IOL POD T 49P in Cataractous Eyes

This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC (model POD T 49P).

Read the detailed description

This is a Multi-center, single-arm and non-masked study whereby patients undergoing routine cataract surgery will be implanted with a hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC. The device under investigation is a hydrophobic acrylic monofocal toric intraocular lens (IOL) manufactured by the sponsor of this study (BVI Medical). The refractive power of the lens has a spherical and a cylindrical component. The IOLs will be implanted in the course of routine cataract surgery and will benefit to patients suffering from cataract development and showing pre-existing corneal astigmatism.

In total approx. 28 patients, 56 eyes will be recruited for this clinical study and undergo implantation of PODEYE TORIC intraocular lens.

Subjects participating in the trial will attend a total of maximum 6 study visits over a period of 120-180 days (preoperative, operative, 1-2 days, 7-14 days, 30-60 days, 120-180 days, postoperative visits). Subjects would have the option for unscheduled visits if required medically.

Being tested
POD T 49P implantation experimental
Keywords
Intraocular Lens, Monofocal, Toric Lens
Medical subject headings
Cataract, Astigmatism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • POD T 49P implantation experimentalDevice

    The investigational lens will be implanted within the capsular bag after removal of the natural crystalline lens following phacoemulsification and alignment the toric axis of investigational lens to the intend axis which was calculated by the Toric calculator software. When enroll the test lenses into both eyes, the lens is implanted first to the eye with more advanced cataract. If both eyes have a similar degree of cataract, perform the surgery first for the right eye. The timing of surgery the investigational lens into the fellow eye will be determined after the investigator and the investigator (hereinafter referred to as the investigator) have confirmed the safety of the previously operated eye.

Study groups in NCT05255029
Study groupRoleWhat they receive
PODEYE Toric Intra Ocular Lens Implantation experimentalExperimentalImplantation of PODEYE toric intraocular lenses.
Receives: Device: POD T 49P implantation experimental

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Uncorrected visual acuity at Visit 4

    Uncorrected visual acuity at 5 m will be measured. Convert decimal visual acuity to logMAR value using the following formula.

    logMAR value = log10 (1/decimal visual acuity)

    Measured: Postoperative Day 120-180

  2. Amount of astigmatism at Visit 4

    Manifest cylindrical refraction for Best Collected Distance Visual Acuity will be measured at Visit 4.

    Measured: Postoperative Day 120-180

Secondary outcomes (3)
  1. Best Corrected Distance Visual Acuity

    Best Corrected Distance Visual Acuity at 5 m will be measured. The objective is to compare CDVA above defined thresholds of the investigational product.

    Measured: Pre-Op, 1 week postoperative, 1 month postoperative, 6 months postoperative.

  2. Manifest cylindrical refraction

    Manifest cylindrical refraction for Best Collected Distance Visual Acuity will be measured.

    Measured: Pre-Op, 1 month postoperative, 6 months postoperative

  3. IOL rotation

    After mydriasis, a photograph of the anterior segment of the test lens is taken using an anterior segment analyzer, and the angle of the toric mark with respect to the horizon is measured as the axial angle. Calculate the number of the eye and the percentage of less than 5 degrees, more than 5 degrees to less than 10 degrees, more than 10 degrees to less than 20 degrees.

    Measured: Pre-Op, 1 month postoperative, 6 months postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Feb 2022
  2. Study start24 Dec 2021
  3. Primary completion28 Feb 2023
  4. Study completion28 Feb 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
1\) Summary of investigational lens Model: POD T 49P General name: PODEYE Toric Construction Single-piece construction lens consisting of the optic and the haptic made of the same material, optic diameter: 6.0 mm, overall length: 11.4 mm (Fig.1). Cylinder power is added on the posterior optics.
Masking
None (open label)
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05255029
Sponsor's protocol ID
PHY2107
Acronym
PHY2107
Status last verified
Jul 2023
First submitted
26 Nov 2021
Last updated
19 Jul 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing POD T 49P implantation experimental in people with Cataract and Lens Opacities, run by Beaver-Visitec International, Inc. at 4 sites in Japan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Uncorrected visual acuity at Visit 4 (time frame: Postoperative Day 120-180). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2023; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in